Multiple Myeloma

Daratumumab for Multiple Myeloma With High-Risk Cytogenetic Factors

By

Vicki Moore, PhD

Publish Date October 8, 2020

The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.

Low Enrollment and Reporting of Racial Minorities in Multiple Myeloma Trials

By

Vicki Moore, PhD

Publish Date October 2, 2020

Multiple myeloma trials appear to underrepresent racial minorities in enrollment and in reporting, with no obvious improvement in recent years.

Analysis of Carfilzomib vs Bortezomib Triplet Therapy for Newly Diagnosed Multiple Myeloma

By

Vicki Moore, PhD

Publish Date September 30, 2020

The superiority of carfilzomib vs bortezomib in triplet therapy was compared in newly diagnosed multiple myeloma ineligible for immediate transplantation.

BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma

By

Brian Park, PharmD

Publish Date September 29, 2020

The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.

Rapid Third-Infusion Protocol of Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma

By

Vicki Moore, PhD

Publish Date September 21, 2020

An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.